GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Cyclically Adjusted Revenue per Share

Sumitomo Pharma Co (Sumitomo Pharma Co) Cyclically Adjusted Revenue per Share : $8.24 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Sumitomo Pharma Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sumitomo Pharma Co's adjusted revenue per share for the three months ended in Dec. 2023 was $1.440. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $8.24 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Sumitomo Pharma Co's average Cyclically Adjusted Revenue Growth Rate was 1.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sumitomo Pharma Co was 5.10% per year. The lowest was 4.00% per year. And the median was 4.30% per year.

As of today (2024-05-01), Sumitomo Pharma Co's current stock price is $2.70. Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $8.24. Sumitomo Pharma Co's Cyclically Adjusted PS Ratio of today is 0.33.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sumitomo Pharma Co was 3.84. The lowest was 0.28. And the median was 1.49.


Sumitomo Pharma Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Cyclically Adjusted Revenue per Share Chart

Sumitomo Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.59 9.82 10.48 9.63 9.60

Sumitomo Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.99 9.60 8.36 8.33 8.24

Competitive Comparison of Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Cyclically Adjusted PS Ratio falls into.



Sumitomo Pharma Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sumitomo Pharma Co's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.44/106.8000*106.8000
=1.440

Current CPI (Dec. 2023) = 106.8000.

Sumitomo Pharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 2.538 95.700 2.832
201406 2.213 98.000 2.412
201409 2.075 98.500 2.250
201412 2.127 97.900 2.320
201503 1.928 97.900 2.103
201506 1.996 98.400 2.166
201509 2.112 98.500 2.290
201512 2.185 98.100 2.379
201603 2.199 97.900 2.399
201606 2.473 98.100 2.692
201609 2.339 98.000 2.549
201612 2.331 98.400 2.530
201703 2.293 98.100 2.496
201706 2.636 98.500 2.858
201709 2.617 98.800 2.829
201712 2.759 99.400 2.964
201803 2.651 99.200 2.854
201806 2.651 99.200 2.854
201809 2.475 99.900 2.646
201812 2.708 99.700 2.901
201903 2.545 99.700 2.726
201906 2.736 99.800 2.928
201909 2.648 100.100 2.825
201912 2.916 100.500 3.099
202003 2.939 100.300 3.129
202006 3.132 99.900 3.348
202009 3.043 99.900 3.253
202012 3.232 99.300 3.476
202103 2.806 99.900 3.000
202106 2.999 99.500 3.219
202109 3.714 100.100 3.963
202112 3.059 100.100 3.264
202203 2.716 101.100 2.869
202206 3.004 101.800 3.152
202209 2.800 103.100 2.900
202212 2.630 104.100 2.698
202303 1.794 104.400 1.835
202306 1.348 105.200 1.369
202309 1.310 106.200 1.317
202312 1.440 106.800 1.440

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Sumitomo Pharma Co  (OTCPK:DNPUF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sumitomo Pharma Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.70/8.24
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sumitomo Pharma Co was 3.84. The lowest was 0.28. And the median was 1.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sumitomo Pharma Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Industry
Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.